Pancreatic lymphoma

Changed by Hamish Smith, 10 Sep 2018

Updates to Article Attributes

Body was changed:

Pancreatic lymphoma is most commonly a B-cell sub-type of non-Hodgkin lymphoma.

Epidemiology

TypicallyPancreatic lymphoma is typically seen in middle-aged patients: with a mean age of around 55 years; range, 35-75 years old and is more common in immunocompromised patients.

Clinical presentation

Presentation isSymptoms are often non-specific. reported symptoms but may include 1:

The classic B-symptoms of non-Hodgkin lymphoma (e.g. fever, chills, night sweats) are present in only 2% of cases 1,2.

Pathology

Aetiology

It is classified as either primary or secondary:

  • primary pancreatic lymphoma is a rare extranodal manifestation of any histopathologic subtype of B-cell non-Hodgkin's lymphoma, representing <2% of extranodal lymphomas and 0.5% of pancreatic tumours 1,2
  • secondary lymphoma: found in 30% of non-Hodgkin lymphoma patients with widespread disease, it is the dominant form and is the result of direct extension from peripancreatic lymphadenopathy 1
Location

Two morphologic patterns of pancreatic lymphoma are recognised 1:

  • focal form: occurs in the pancreatic head in 80% of cases and has a mean size of 8 cm
  • diffuse form: infiltrative, leading to glandular enlargement and poor definition, features that can simulate the appearance of acute pancreatitis

Radiographic features

CT
  • minimal enhancement
  • peripancreatic lymph node enlargement
  • it typically has uniform low attenuation
  • diffuse enlargement (diffuse form) may simulate acute pancreatitis
  • encasement of the peripancreatic vessels may occur; vascular invasion is less common in lymphoma than in adenocarcinoma 1-2
MRI
  • focal form: low signal intensity on T1-weighted images and intermediate signal intensity on T2-weighted images (slightly higher signal intensity than the pancreas but lower signal intensity than fluid), and shows faint contrast enhancement 1
  • diffuse form: low signal intensity on T1- and T2-weighted MR images and shows homogeneous contrast enhancement, although small foci of reduced or absent enhancement are sometimes seen 1

Treatment and prognosis

Percutaneous or endoscopic core biopsy should be performed to establish the diagnosis 2.

Pancreatic lymphoma carries a better prognosis than adenocarcinoma because first-line treatment with chemotherapy is generally effective in producing long-term disease regression or remission. Surgery is not required in most cases 1.

Using complex treatment approaches, cure rates of up to 30% are reported for patients with primary pancreatic lymphoma. This prognosis is much better than the dismal 5% 5-year survival rate in patients with pancreatic adenocarcinoma 2.

Differential diagnosis

Imaging differential considerations include

For a diffuse bulkiness to the pancreas consider

  • -<p><strong>Pancreatic lymphoma</strong> is most commonly a B-cell sub-type of non-Hodgkin <a href="/articles/lymphoma">lymphoma</a>.</p><h4>Epidemiology</h4><p>Typically seen in middle-aged patients: mean of 55 years; range, 35-75 years and in immunocompromised patients.</p><h4>Clinical presentation</h4><p>Presentation is often non-specific. reported symptoms include <sup>1</sup>:</p><ul>
  • -<li>abdominal pain: ~ 85%</li>
  • -<li>mass: ~ 60%</li>
  • -<li>weight loss: ~ 50%</li>
  • +<p><strong>Pancreatic lymphoma</strong> is most commonly a B-cell sub-type of non-Hodgkin <a href="/articles/lymphoma">lymphoma</a>.</p><h4>Epidemiology</h4><p>Pancreatic lymphoma is typically seen in middle-aged patients with a mean age of around 55 years old and is more common in immunocompromised patients.</p><h4>Clinical presentation</h4><p>Symptoms are often non-specific but may include <sup>1</sup>:</p><ul>
  • +<li>abdominal pain ~ 85%</li>
  • +<li>mass ~ 60%</li>
  • +<li>weight loss ~ 50%</li>
  • -<a href="/articles/jaundice">obstructive jaundice</a>: ~ 40% of cases</li>
  • -<li>acute <a href="/articles/acute-pancreatitis">pancreatitis</a>: ~ 10% </li>
  • +<a href="/articles/jaundice">obstructive jaundice</a> ~ 40% of cases</li>
  • +<li>acute <a href="/articles/acute-pancreatitis">pancreatitis</a> 10% </li>
  • -<a title=" pancreatic adenocarcinoma" href="/articles/pancreatic-adenocarcinoma"> pancreatic adenocarcinoma</a> <sup>3</sup>
  • +<a href="/articles/pancreatic-adenocarcinoma">pancreatic adenocarcinoma</a> <sup>3</sup>

ADVERTISEMENT: Supporters see fewer/no ads

Updating… Please wait.

 Unable to process the form. Check for errors and try again.

 Thank you for updating your details.